Envestnet Asset Management Inc. Sells 139,697 Shares of Stevanato Group S.p.A. (NYSE:STVN)

Envestnet Asset Management Inc. lowered its stake in Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 50.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 139,225 shares of the company's stock after selling 139,697 shares during the quarter. Envestnet Asset Management Inc.'s holdings in Stevanato Group were worth $3,034,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of STVN. Wells Fargo & Company MN increased its position in shares of Stevanato Group by 680.3% during the fourth quarter. Wells Fargo & Company MN now owns 3,246 shares of the company's stock worth $71,000 after acquiring an additional 2,830 shares in the last quarter. Cinctive Capital Management LP increased its holdings in Stevanato Group by 241.3% during the 4th quarter. Cinctive Capital Management LP now owns 83,156 shares of the company's stock worth $1,812,000 after purchasing an additional 58,792 shares in the last quarter. Allianz SE purchased a new stake in shares of Stevanato Group in the fourth quarter worth approximately $748,000. Blair William & Co. IL bought a new position in shares of Stevanato Group in the fourth quarter valued at approximately $466,000. Finally, Artisan Partners Limited Partnership boosted its position in shares of Stevanato Group by 28.7% during the fourth quarter. Artisan Partners Limited Partnership now owns 2,355,799 shares of the company's stock valued at $51,333,000 after buying an additional 524,989 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. UBS Group dropped their price objective on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a research note on Friday, March 7th. Stephens raised shares of Stevanato Group to a "strong-buy" rating in a research report on Monday, April 21st. Finally, William Blair reissued an "outperform" rating on shares of Stevanato Group in a research report on Friday, March 7th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of €25.70 ($29.20).

Stevanato Group Stock Performance

Shares of STVN stock traded down €0.58 ($0.66) on Tuesday, hitting €21.00 ($23.86). 338,936 shares of the stock were exchanged, compared to its average volume of 342,987. The firm has a market capitalization of $6.36 billion, a PE ratio of 44.68, a P/E/G ratio of 7.18 and a beta of 0.52. Stevanato Group S.p.A. has a one year low of €16.56 ($18.82) and a one year high of €28.77 ($32.69). The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The firm's 50 day moving average is €20.79 and its two-hundred day moving average is €20.79.

Stevanato Group (NYSE:STVN - Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.23) earnings per share (EPS) for the quarter, meeting the consensus estimate of €0.20 ($0.23). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The company had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. Sell-side analysts expect that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.